Asset
Lasmecabtagene Timgedleucel
Cellectis S.A. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04150497 | phase1_2 | recruiting | 2019-10-14 | 2026-06-30 | Cellectis S.A. | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) |
FDA applications (0)
This company has no applications containing this asset.